STAT+: Alnylam versus BridgeBio: The ATTR-CM debate

I coined the term “Typo-gate” to describe the misguided dustup Alnylam Pharmaceuticals executives instigated last Friday when they asserted cardiologist Sarah Cuddy made mistakes during her discussant’s talk following the presentation of the vutrisiran HELIOS-B study results.

The final verdict is the opposite. Alnylam was wrong, Cuddy was right. 

A cardiologist at Brigham and Women’s Hospital, Cuddy performed her own analysis comparing all-cause mortality for vutrisiran and BridgeBio’s competing drug acoramidis, based on data from their respective placebo-controlled Phase 3 studies in ATTR-CM, an increasingly diagnosed heart disease. 

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Alnylam versus BridgeBio: The ATTR-CM debate »